Rockefeller Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Rockefeller Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,634	Closed	-$830K	–	4740
2026 Q1	$830K	Buy	20,634 +20,131	+4,002%	+$434K	﹤0.01%	1702
2025 Q4	$12.6K	Sell	503 -527	-51%	-$12.4K	﹤0.01%	3700
2025 Q3	$23.3K	Buy	+1,030	New	+$24K	﹤0.01%	3291
2023 Q1	–	Sell	-167	Closed	-$8K	–	2073
2022 Q4	$8K	Buy	167 +135	+422%	+$7.16K	﹤0.01%	3157
2022 Q3	$2K	Sell	32 -35	-52%	-$2.07K	﹤0.01%	3552
2022 Q2	$3K	Sell	67 -44	-40%	-$2.01K	﹤0.01%	3618
2022 Q1	$5K	Sell	111 -161	-59%	-$7.11K	﹤0.01%	3315
2021 Q4	$12K	Buy	272 +262	+2,620%	+$10.3K	﹤0.01%	2871
2021 Q3	$0	Hold	10	–	–	﹤0.01%	3682
2021 Q2	$0	Buy	+10	New	+$516	﹤0.01%	3428

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rockefeller Capital Management's APLS Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 20,634 shares — an estimated $830K sold.

Rockefeller Capital Management first reported a position in APLS in Q2 2021 and held it in 10 quarters. The position peaked at $830K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Rockefeller Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Rockefeller Capital Management sold 20,634 Apellis Pharmaceuticals shares in Q2 2026, an estimated $830K.
Rockefeller Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Rockefeller Capital Management's Apellis Pharmaceuticals position peaked at $830K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.